Header Image: Dr Michelle Perugini, SBE by Springboard Enterprises Life Sciences Alumna, 2019.
The SBE by Springboard Enterprises Life Sciences program goes from strength to strength each year.
As we see a rise in the need for innovative health technology and digital medical technology, we're seeing a rise in women founding and running businesses that help solve problems in the life sciences' industries.
Here at SBE, we thrive on being able to assist these women by providing the tools, knowledge and global networks to scale, grow and excel.
Our life sciences executive committee are incredibly well connected life science professionals. It comprises some of the brightest brains in life sciences in Australia. They're global leaders in their thought and success, and we're thrilled to be able to connect them with the up and coming founders and leaders that take part in our SBE by Springboard Life Sciences program. Our participants and alumnae benefit from access to these networks here in Australia. In addition, the Springboard Enterprises network across the US is expansive. You can learn more about the Springboard Enterprises network here.
Introducing our Life Sciences Executive Committee.
Jenny Petering is a registered Australian and New Zealand Patent Attorney, with extensive experience in managing international patent portfolios in the biotechnology space, including strategic planning, due diligence, infringement and patentability advice, and coordinating opposition proceedings. With vast experience managing extensive portfolios, Jenny act's for a broad range of clients including universities, hospitals, co-operative research centres, research institutes and corporates, ranging from start-up companies through to large global entities.
A partner with FB Rice for 15 years, Jenny is now Of Counsel with the firm and actively involved in pursuing external activities supporting the advancement of the biotechnology industry. She frequently presents seminars and speaks on panels around the world on various patent and intellectual property strategy topics and am a Senior Fellow in the Melbourne Law Masters program at Melbourne University.
She is also involved with a number of leading industry groups and have expert panel positions for the Industry Mentoring Network in Stem as well as the Science, Medical Research and Technology (SmaRT) Panel. Jenny's involvement with Scale Angels supports early stage companies with advice and mentoring, connecting entrepreneurs to strategic partners and access to funding.
Sam Cobb is an accomplished and results driven executive, focused on the commercialisation of science-based technologies.
As founding CEO and Managing Director of AdAlta (ASX: 1AD), over a 12-year period she has seen AdAlta through several transitions. From start-up, to an ASX listing and raising >$30m in equity funding during her tenure. Sam took an idea from the bench to an advanced lead candidate that is Phase I-ready and secured multiple big pharma and biotech deals with the company’s novel biologics platform including GE Healthcare.
Over her 23-year career in the biotech sector she has enjoyed working in several start-up environments across multiple areas of science. Across roles, Sam has identified commercial opportunities, built businesses from scratch, raised money and licensed technology, securing non-dilutive funding from major pharma and biotech companies and via grants. Bringing together her science and law backgrounds together, Sam is focused on commercially driven outcomes and paths to market.
Sam is strong in project management and provides clear leadership to take teams through major operational challenges. A solid communicator, She has developed exceptional relationships with stakeholders central to her roles and have a broad network as a result.
Australian biotechnology Company Director and CEO with more than 25 years of experience including in 4 ASX listed biotechnology companies and 9 years of patent attorney practice. Scientist and Patent Attorney by training, Kathy has successfully delivered pre-clinical assets through phase 2, and transitioned companies through critical drug development stages. With a track record in creating value in life sciences companies, both in strategic guidance and operational success in drug development programs and corporate transactions, Kathy has the skills and experience to build teams and execute on commercial timelines.
Kathy was selected to participate in the inaugural 2018 SBE Australia Life Sciences Accelerator Program, and is now part of the prestigious US Springboard Alumni Network.
Under Kathy's leadership, Dimerix was a 2018 Westpac Business of Tomorrow (200) winner.
Specialties: Accelerating clinical treatment opportunities through critical milestones. Identifying and executing on niche intellectual property opportunities. Building and leading teams. Identification of efficient approaches to drug development opportunities and delivering on project outcomes.
Sharon Charles is a seasoned strategically-focused director-level Biotech / Pharmaceutical industry corporate leader. With a breadth and depth of 29 years’ experience in the healthcare sector across geographies (global), functions (corporate, clinical, medical affairs, sales/marketing, corporate communications, BD), strength in clinical and commercial development, strategic information management and M&A diligence and integration.
Sharon is a well-connected, strong advocate for Australian biotech and pharmaceutical R&D, including industry presentations and input into government strategic think-tanks. She has a strong track record in leading teams and achieving corporate growth, building corporate infrastructure and world-class products and services, developing and growing the regional business from the ground-up. She also has experience working in hospitals, pharmaceutical and biotech companies, and leading organisations undergoing rapid growth and change.
The digitally connected world is the new frontier for all industries, but particularly healthcare, to master to stay relevant, valued and invested in. Michelle's current role is in leading and scaling an emerging company that uses artifical intelligence to analyse and understand content shared publicly to social media. Their point of difference is their ability to compliantly use social networks to activate and improve the health and wellness experience and access for patients, providers and caregivers.
After 25 years in biopharma marketing and advocacy, Michelle recognised the emergence and strength of social media as one of the most powerful marketing communication and industry engagement tools since newsprint, founding The Social Science in 2014. At the same time The Social Science was being built, she co-founded Women in STEMM Australia, a NFP advocating for a greater representation of women in STEMM leadership roles in Australia and helping to stem the tide of women dropping out of STEMM mid career. Michelle also has a third startup - SkinLife - because everyone needs a side hustle.
In 2018, Michelle successfully sold The Social Science to ShareRoot (ASX:SRO) merging two smart, rapidly developing businesses now with the technology and service skills to accelerate compliant, ethical digital marketing. In March 2019 she took over the lead of ShareRoot and then restructured, recalibrated the strategy to focus exclusively in healthcare, finally rebranding the business as Opyl Ltd (ASX:OPL) in early November 2019.
Michelle's passionate about small business and entrepreneurship, AI, ethical digital marketing and communications and leadership in a digital economy. She wants to see social media used creatively and effectively as a tool in improving public health, amplifying research, clinical studies, patient support, industry engagement, informed opinion leadership and science advocacy. She's a champion for Women in STEMM and strives to level the playing field to ensure women have an equal future in innovation, and that diversity and inclusion are more than buzz words.